Compare UVV & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UVV | GLUE |
|---|---|---|
| Founded | 1886 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | UVV | GLUE |
|---|---|---|
| Price | $58.65 | $19.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 175.8K | ★ 2.7M |
| Earning Date | 02-09-2026 | 03-19-2026 |
| Dividend Yield | ★ 5.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.44 | 0.25 |
| Revenue | ★ $2,987,411,000.00 | $181,538,000.00 |
| Revenue This Year | $3.21 | $84.02 |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | ★ $13.24 | $77.41 |
| Revenue Growth | 3.01 | ★ 1112.27 |
| 52 Week Low | $49.96 | $3.50 |
| 52 Week High | $67.33 | $25.77 |
| Indicator | UVV | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 76.72 | 44.37 |
| Support Level | $53.63 | $19.91 |
| Resistance Level | $56.20 | $21.69 |
| Average True Range (ATR) | 0.93 | 1.39 |
| MACD | 0.37 | -0.63 |
| Stochastic Oscillator | 90.14 | 8.72 |
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.